Arkolith/Insider Trading/ALLO/Form 4

Chang David D

President and CEO, DirectorAllogene Therapeutics, Inc. (ALLO) · full profile →Form 4 · filed Feb 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$171K
Net Open-Market Flow
-$171K
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2026Sell(S)95K$1.80$171K5.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 2, 2026Grant(A)1.4M—$01.4M
Feb 2, 2026Grant(A)393K—$0393K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001737287-26-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML